GlassScriptPhysician profile
Muhammad I Kafeel
NPI 1174756423
$7,010.43
in general payments reported to CMS, 2019-2025
47 companies · $2,058 in 2025
The $2,058 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,520 · 2020: $486 · 2021: $369 · 2022: $1,181 · 2023: $964 · 2024: $433 · 2025: $2,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221 · Long Term Medical Supply Or Device Loan: $897 · Education: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.03 |
| Long Term Medical Supply Or Device Loan | $897.30 |
| Education | $335.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,614.35 | 2019-2025 | |
| Janssen Biotech, INC. | $855.09 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $524.64 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $392.99 | 2019-2025 | Opdivo, Reblozyl, Augtyro |
| Incyte Corporation | $332.03 | 2021-2025 | Jakafi |
| Genzyme Corporation | $283.60 | 2022-2025 | |
| Amarin Pharma, INC. | $249.07 | 2019 | |
| Pfizer INC. | $212.24 | 2019-2025 | |
| Astellas Pharma US INC | $184.63 | 2019-2025 | Xtandi |
| Lilly USA, LLC | $162.92 | 2019-2022 | |
| Celgene Corporation | $149.61 | 2019-2024 | Pomalyst, Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $147.37 | 2019-2020 | |
| Puma Biotechnology, INC. | $134.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.46 | 2019-2025 | Iclusig |
| Merck Sharp & Dohme LLC | $127.27 | 2019-2025 | Keytruda, Keytruda Qlex |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Kafeel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.